Literature DB >> 15358324

Survival and functional quality of life after resection for hepatic carcinoid metastasis.

Clayton D Knox1, Irene D Feurer, Paul E Wise, Laura W Lamps, J Kelly Wright, Ravi S Chari, D Lee Gorden, C Wright Pinson.   

Abstract

Retrospective studies suggest that resection improves 5-year survival for patients with hepatic carcinoid metastasis (HCM). The purpose of our study was to describe clinical outcomes following resection for HCM, including survival and longitudinal functional quality of life (QOL). We reviewed the records of patients undergoing resection for HCM from 1980 to 2001 at our institution. Outcome measures included tumor symptoms, biochemical tumor markers, functional QOL through Karnofsky functional scores, and survival. Thirteen patients underwent a total of 17 resections. Overall 5-year survival was 85%. Eleven patients were symptomatic, including eight with classic carcinoid syndrome. Nine experienced complete relief of symptoms and two had incomplete relief for 30 +/- 12 months. Eight patients had elevated tumor markers, and 50% of these had postoperative normalization of all tumor markers that persisted to the close of the study. For the 10 patients with longitudinal follow-up available to 54 months, significant improvement in functional QOL was observed at all follow-up time points compared to preresection functional QOL (P < 0.05). Resection of >/=90% tumor volume was significantly associated with more favorable survival and tumor marker normalization compared to resection of <90% tumor volume (P < 0.01 and P < 0.05, respectively), but trajectory of functional QOL improvement did not differ between these two groups (P=0.24). We conclude that resection for HCM is associated with significantly improved and sustained functional QOL and prolonged survival. Resection of >/=90% tumor volume is significantly associated with extended survival and normalization of tumor markers, but is not required for symptomatic or functional QOL improvement.

Entities:  

Mesh:

Year:  2004        PMID: 15358324     DOI: 10.1016/j.gassur.2004.04.003

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  25 in total

1.  Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors.

Authors:  O Søreide; T Berstad; A Bakka; E Schrumpf; L E Hanssen; V Engh; A Bergan; A Flatmark
Journal:  Surgery       Date:  1992-01       Impact factor: 3.982

2.  Prognosis and survival in patients with gastrointestinal tract carcinoid tumors.

Authors:  K O Shebani; W W Souba; D M Finkelstein; P C Stark; K M Elgadi; K K Tanabe; M J Ott
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

Review 3.  Therapeutic alternatives in metastatic neuroendocrine tumors.

Authors:  C A Miller; E C Ellison
Journal:  Surg Oncol Clin N Am       Date:  1998-10       Impact factor: 3.495

4.  Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients.

Authors:  S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

Review 5.  Complications of hepatic cryosurgery.

Authors:  T Sarantou; A Bilchik; K P Ramming
Journal:  Semin Surg Oncol       Date:  1998-03

6.  Hepatic neuroendocrine metastases: does intervention alter outcomes?

Authors:  R S Chamberlain; D Canes; K T Brown; L Saltz; W Jarnagin; Y Fong; L H Blumgart
Journal:  J Am Coll Surg       Date:  2000-04       Impact factor: 6.113

7.  Cytoreductive hepatic surgery for neuroendocrine tumors.

Authors:  G P McEntee; D M Nagorney; L K Kvols; C G Moertel; C S Grant
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

8.  Hepatic resection for metastatic neuroendocrine carcinomas.

Authors:  F G Que; D M Nagorney; K P Batts; L J Linz; L K Kvols
Journal:  Am J Surg       Date:  1995-01       Impact factor: 2.565

9.  Hepatic cryotherapy: double-freeze cycles achieve greater hepatocellular injury in man.

Authors:  G J Stewart; A Preketes; M Horton; W B Ross; D L Morris
Journal:  Cryobiology       Date:  1995-06       Impact factor: 2.487

10.  Carcinoid tumors of the gastrointestinal tract: presentation, management, and prognosis.

Authors:  G B Thompson; J A van Heerden; J K Martin; A J Schutt; D M Ilstrup; J A Carney
Journal:  Surgery       Date:  1985-12       Impact factor: 3.982

View more
  7 in total

Review 1.  When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations.

Authors:  Mickaël Lesurtel; David M Nagorney; Vincenzo Mazzaferro; Robert T Jensen; Graeme J Poston
Journal:  HPB (Oxford)       Date:  2014-03-17       Impact factor: 3.647

2.  Quality of life after curative liver resection: a single center analysis.

Authors:  Helge Bruns; Kirsten Krätschmer; Ulf Hinz; Anette Brechtel; Monika Keller; Markus-W Büchler; Peter Schemmer
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

3.  Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population.

Authors:  Trude Haugland; Morten H Vatn; Marijke Veenstra; Astrid Klopstad Wahl; Gerd Karin Natvig
Journal:  Qual Life Res       Date:  2009-05-29       Impact factor: 4.147

4.  Surgical treatment of neuroendocrine liver metastases.

Authors:  Ser Yee Lee; Peng Chung Cheow; Jin Yao Teo; London L P J Ooi
Journal:  Int J Hepatol       Date:  2012-01-26

5.  Surgical treatment of liver metastases in neuroendocrine neoplasms.

Authors:  Palepu Jagannath; Deepak Chhabra; Shailesh Shrikhande; Rajiv Shah
Journal:  Int J Hepatol       Date:  2012-01-26

6.  A case of early-stage ovarian carcinoid tumor metastasized to the liver.

Authors:  Seiji Kanayama; Yoshihiko Yamada; Yasuhito Tanase; Shoji Haruta; Akira Nagai; Ryuji Kawaguchi; Shozo Yoshida; Naoto Furukawa; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Case Rep Obstet Gynecol       Date:  2012-12-26

Review 7.  The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012.

Authors:  Daniela Macedo; Teresa Amaral; Isabel Fernandes; Ana Rita Sousa; Ana Lúcia Costa; Isabel Távora; António Quintela; Paulo Cortes; Luís Costa
Journal:  ISRN Hepatol       Date:  2013-02-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.